disease Phospholipase A 2 levels in acute chest syndrome of sickle cell

http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub_requests Information about reproducing this article in parts or in its entirety may be found online at: http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#reprints Information about ordering reprints may be found online at: http://bloodjournal.hematologylibrary.org/site/subscriptions/index.xhtml Information about subscriptions and ASH membership may be found online at:

[1]  J. Esterly,et al.  Pulmonary changes in sickle cell disease. , 2015, The American review of respiratory disease.

[2]  J. Hermon-Taylor,et al.  Type 1 prophospholipase A2 propeptide in acute lung injury , 1994, The Lancet.

[3]  R. Siegel,et al.  Elevated urinary levels of thromboxane and prostacyclin metabolites in sickle cell disease reflects activated platelets in the circulation , 1994, British journal of haematology.

[4]  O. Platt,et al.  Mortality in sickle cell disease. Life expectancy and risk factors for early death. , 1994, The New England journal of medicine.

[5]  E. Vichinsky,et al.  Pulmonary fat embolism: a distinct cause of severe acute chest syndrome in sickle cell anemia. , 1994, Blood.

[6]  E. Dennis.  Diversity of group types, regulation, and function of phospholipase A2. , 1994, The Journal of biological chemistry.

[7]  J. Raj,et al.  Plasma and urinary leukotrienes in sickle cell disease: possible role in the inflammatory process , 1994, European journal of clinical investigation.

[8]  T. Nevalainen.  Serum phospholipases A2 in inflammatory diseases. , 1993, Clinical chemistry.

[9]  M. Fink.  Phospholipases A2: potential mediators of the systemic inflammatory response syndrome and the multiple organ dysfunction syndrome. , 1993, Critical care medicine.

[10]  P. Vadas,et al.  Association of hyperphospholipasemia A2 with multiple system organ dysfunction due to salicylate intoxication. , 1993, Critical care medicine.

[11]  J. Maclouf,et al.  Increased in vivo production of thromboxane in patients with sickle cell disease is accompanied by an impairment of platelet functions to the thromboxane A2 agonist U46619. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[12]  P. Vadas,et al.  Induction of circulating group II phospholipase A2 expression in adults with malaria , 1992, Infection and immunity.

[13]  E. Moore,et al.  Phospholipase A2 inhibition decouples lung injury from gut ischemia-reperfusion. , 1992, Surgery.

[14]  L. Haywood,et al.  Elevated immunoreactive tumor necrosis factor and interleukin-1 in sickle cell disease. , 1992, Journal of the National Medical Association.

[15]  A. Mukherjee,et al.  Regulation of extracellular phospholipase A2 activity: implications for inflammatory diseases. , 1992, DNA and cell biology.

[16]  R. Ward,et al.  Measurement of human phospholipase A2 in arthritis plasma using a newly developed sandwich ELISA. , 1992, British journal of rheumatology.

[17]  R. Lee,et al.  Circulating phospholipase A2 activity associated with sepsis and septic shock is indistinguishable from that associated with rheumatoid arthritis , 1991, Inflammation.

[18]  W. Regelson,et al.  Mechanism(s) of cytoprotective and anti-inflammatory activity of PGB1 oligomers: PGBx has potent anti-phospholipase A2 and anti-oxidant activity. , 1991, Prostaglandins, leukotrienes, and essential fatty acids.

[19]  S. Oka,et al.  Inflammatory factors stimulate expression of group II phospholipase A2 in rat cultured astrocytes. Two distinct pathways of the gene expression. , 1991, The Journal of biological chemistry.

[20]  W. Henderson.  Eicosanoids and platelet-activating factor in allergic respiratory diseases. , 1991, The American review of respiratory disease.

[21]  P. Vadas,et al.  Acute lung injury induced by phospholipase A2. Structural and functional changes. , 1991, The American review of respiratory disease.

[22]  P. Vadas,et al.  The role of phospholipase A2 in the physiopathology of osteoarthritis. , 1991, The Journal of rheumatology. Supplement.

[23]  M. Büchler,et al.  Serum phospholipase A2 in patients with multiple injuries. , 1990, The Journal of trauma.

[24]  Robert A. Lewis,et al.  Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. , 1990, The New England journal of medicine.

[25]  M. Dick,et al.  Endotoxinaemia in sickle cell disease. , 1988, Clinical and laboratory haematology.

[26]  S. Crooke,et al.  Tumour necrosis factor (cachectin) induces phospholipase A2 activity and synthesis of a phospholipase A2-activating protein in endothelial cells. , 1988, The Biochemical journal.

[27]  J. Niland,et al.  Sickle Cell Chronic Lung Disease: Prior Morbidity and the Risk of Pulmonary Failure , 1988, Medicine.

[28]  C. Herzog,et al.  [Interleukin 1 and tumor necrosis factor]. , 1987, Zeitschrift fur Rheumatologie.

[29]  C. R. Patterson,et al.  Fat embolism syndrome: Prospective evaluation in 92 fracture patients , 1987, Critical care medicine.

[30]  W. Henderson,et al.  Eicosanoids and lung inflammation. , 1987, The American review of respiratory disease.

[31]  W. Henderson,et al.  Lipid-derived and other chemical mediators of inflammation in the lung. , 1987, The Journal of allergy and clinical immunology.

[32]  M. Poncz,et al.  Acute chest syndrome in sickle cell disease: etiology and clinical correlates. , 1985, The Journal of pediatrics.

[33]  G. Maude,et al.  Pneumonia in young children with homozygous sickle cell disease: risk and clinical features , 1985, European Journal of Pediatrics.

[34]  C. Holtkamp,et al.  Plasma Levels of Platelet and Vascular Prostaglandin Derivatives in Children with Sickle Cell Anaemia , 1985, Thrombosis and Haemostasis.

[35]  P. Vadas.  Elevated plasma phospholipase A2 levels: correlation with the hemodynamic and pulmonary changes in gram-negative septic shock. , 1984, The Journal of laboratory and clinical medicine.

[36]  P. Vadas,et al.  Involvement of circulating phospholipase A2 in the pathogenesis of the hemodynamic changes in endotoxin shock. , 1983, Canadian journal of physiology and pharmacology.

[37]  E. Kivilaakso,et al.  Serum phospholipase A2 and pulmonary changes in acute fulminant pancreatitis. , 1982, Resuscitation.

[38]  M. Birnbaum,et al.  Fat emboli syndrome. , 1976, The Journal of trauma.

[39]  L. van Deenen,et al.  Isolation and properties of a phospholipase A1 activity from beef pancreas. , 1974, Biochimica et biophysica acta.

[40]  J. White,et al.  Fat embolism in sickle cell disease , 1973, Journal of clinical pathology.

[41]  L. Peltier.  The diagnosis and treatment of fat embolism. , 1971, The Journal of trauma.

[42]  C. M. Evarts.  The fat embolism syndrome: a review. , 1970, The Surgical clinics of North America.

[43]  J. Parker-Williams,et al.  A phospholipase inhibitor modifies the pulmonary damage associated with peritonitis in rabbits , 2004, Intensive Care Medicine.

[44]  Robert,et al.  Induction of Phospholipase A 2 Gene Expression in Human Hepatoma Cells by Mediators of the Acute Phase Response * , 2001 .

[45]  D. Schuster.  ARDS: clinical lessons from the oleic acid model of acute lung injury. , 1994, American journal of respiratory and critical care medicine.

[46]  J. Weil,et al.  NHLBI Workshop Summary. Pathogenesis of lung disease in sickle hemoglobinopathies. , 1993, The American review of respiratory disease.

[47]  P. Vadas,et al.  Phospholipase A2--a mediator between proximal and distal effectors of inflammation. , 1991, Immunology today.

[48]  K. Glaser,et al.  Macrophage phospholipase A2 activity and eicosanoid production: studies with phospholipase A2 inhibitors in P388D1 cells. , 1990, Advances in experimental medicine and biology.

[49]  E. Dennis,et al.  Activation, aggregation, inhibition and the mechanism of phospholipase A2. , 1990, Advances in experimental medicine and biology.

[50]  L. Marshall,et al.  Pharmacological control of phospholipase A2 activity in vitro and in vivo. , 1990, Advances in experimental medicine and biology.

[51]  D. Niewoehner,et al.  Induction of alveolar epithelial injury by phospholipase A2. , 1989, Journal of applied physiology.

[52]  P. Vadas,et al.  Pathogenesis of hypotension in septic shock: correlation of circulating phospholipase A2 levels with circulatory collapse. , 1988, Critical care medicine.

[53]  M. Harpen,et al.  Magnetic resonance imaging, percentage of dense cells and serum prostanoids as tools for objective assessment of pain crisis: a preliminary report. , 1987, Progress in clinical and biological research.

[54]  S. Charache,et al.  "Acute chest syndrome" in adults with sickle cell anemia. Microbiology, treatment, and prevention. , 1979, Archives of internal medicine.

[55]  L. P. Leblanc,et al.  Subclinical fat embolism: a prospective study of 50 patients with extremity fractures. , 1973, The Journal of trauma.